Anti-glaucoma Agent

Natural or synthetic Anti-glaucoma Agents relieve or prevent glaucoma, a condition characterized by increased intraocular pressure, excavation, and… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

1984-2018
01219842018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Long-term treatment of glaucoma, a major leading cause of blindness, is challenging due to poor patient compliance. Therefore, a… (More)
Is this relevant?
2014
2014
Glaucoma is the second leading cause of blindness in the US. Brimonidine tartrate (BT) is a modern anti-glaucoma agent that is… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2014
2014
Nipradilol (Nip) is registered as an anti-glaucoma agent. More recently, a protective effect of Nip has been demonstrated in… (More)
Is this relevant?
2010
2010
To evaluate the pharmacological properties of cilostazol (CLZ), we examined its intraocular pressure (IOP) -lowering effect. CLZ… (More)
Is this relevant?
Review
2008
Review
2008
My prime years as an ophthalmologist began as intraocular lenses (IOLs) were just entering into the developmental stage, and I… (More)
Is this relevant?
2004
2004
BACKGROUND Diffuse lamellar keratitis (DLK) is a relatively uncommon complication of the refractive procedure, laser-assisted in… (More)
Is this relevant?
2001
2001
A 1-month-old infant with Peters anomaly had recurrent episodes of unresponsiveness, hypotension, hypotonia, hypothermia, and… (More)
Is this relevant?
2000
2000
Cannabinoids have intraocular pressure (IOP) lowering effects, thus, they have a therapeutic potential in the treatment of… (More)
Is this relevant?
1994
1994
We studied the effect of UF-021, a prostaglandin-related compound under application as an anti-glaucoma agent, on the circulation… (More)
Is this relevant?
1993
1993
We administered UF-021 isopropyl unoprostone (Rescula) ophthalmic solution, a new prostaglandin-related compound developed as an… (More)
Is this relevant?